## 18. Full Bidirectional Feature Symmetry

### Principle

**Whatever a GP can do with LPs, an LP should be able to do with GPs.**

This section documents the complete feature mapping between GPâ†’LP and LPâ†’GP directions.

---

### 18.1 Feature Symmetry Matrix

| GP Feature | LP Equivalent | Status |
|------------|---------------|--------|
| GP Dashboard | LP Dashboard | Mockup exists |
| Fund Profile | Mandate Profile | Mockup exists |
| LP Recommendations | GP/Fund Recommendations | Planned (M5) |
| LP Shortlist | Fund Watchlist | Mockup exists |
| Pitch Generation | Meeting Request Generation | NEW |
| Outreach Pipeline | Inbound Interest Pipeline | NEW |
| Email Sync | Email Sync | Same feature |
| Calendar Integration | Calendar Integration | Same feature |
| GP Health Dashboard | LP Health Dashboard | Section 17 |
| Team Management | Team Management | Same feature |

---

### 18.2 Dashboard Symmetry

#### GP Dashboard
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ GP Dashboard                                                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                  â”‚
â”‚ YOUR FUNDS                              ACTIVE OUTREACH          â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”              â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ Growth Fund III       â”‚              â”‚ To Contact: 12        â”‚â”‚
â”‚ â”‚ $500M target          â”‚              â”‚ Awaiting Reply: 8     â”‚â”‚
â”‚ â”‚ 47 LP matches         â”‚              â”‚ Meetings Set: 3       â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜              â”‚ In DD: 2              â”‚â”‚
â”‚                                        â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                  â”‚
â”‚ TOP LP RECOMMENDATIONS                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ 1. CalPERS        Score: 92   [View] [Add to Shortlist]     â”‚ â”‚
â”‚ â”‚ 2. Yale Endow.    Score: 88   [View] [Add to Shortlist]     â”‚ â”‚
â”‚ â”‚ 3. Ontario Teach. Score: 85   [View] [Add to Shortlist]     â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

#### LP Dashboard (Mirror)
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ LP Dashboard                                                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                  â”‚
â”‚ YOUR MANDATES                           INBOUND INTEREST         â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”              â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ PE Allocation 2025    â”‚              â”‚ New Requests: 15      â”‚â”‚
â”‚ â”‚ $200M to deploy       â”‚              â”‚ Under Review: 8       â”‚â”‚
â”‚ â”‚ 34 fund matches       â”‚              â”‚ Meetings Set: 4       â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜              â”‚ In DD: 2              â”‚â”‚
â”‚                                        â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                  â”‚
â”‚ TOP FUND RECOMMENDATIONS                                         â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ 1. Acme Fund III    Score: 94   [View] [Add to Watchlist]   â”‚ â”‚
â”‚ â”‚ 2. Growth Partners  Score: 89   [View] [Add to Watchlist]   â”‚ â”‚
â”‚ â”‚ 3. Venture X        Score: 86   [View] [Add to Watchlist]   â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                                  â”‚
â”‚ GPs REQUESTING MEETINGS                                          â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ 1. Blue Capital    Fund IV    Requested: Dec 20             â”‚ â”‚
â”‚ â”‚    Match: 87       [Decline] [Schedule Meeting]             â”‚ â”‚
â”‚ â”‚ 2. Peak Ventures   Fund II    Requested: Dec 19             â”‚ â”‚
â”‚ â”‚    Match: 82       [Decline] [Schedule Meeting]             â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### 18.3 Profile Symmetry

#### GP: Fund Profile
- Fund name, size, vintage
- Strategy, geography, sectors
- Thesis/approach description
- Track record
- Team members
- Documents (pitch deck, DDQ)

#### LP: Mandate Profile
- Mandate name, allocation amount
- Target strategies, geographies
- Mandate constraints
- Investment criteria
- Decision makers
- Documents (investment policy)

---

### 18.4 Matching Symmetry

#### GP â†’ LP Matching
```
GP Fund Profile
    â†“
Matching Algorithm
    â†“
Ranked LP List (by fit score)
    â†“
GP Reviews & Shortlists
    â†“
GP Initiates Outreach
```

#### LP â†’ GP Matching
```
LP Mandate Profile
    â†“
Matching Algorithm
    â†“
Ranked Fund List (by fit score)
    â†“
LP Reviews & Watchlists
    â†“
LP Requests Meetings OR Accepts GP Requests
```

---

### 18.5 Outreach/Interest Pipeline Symmetry

#### GP: Outreach Pipeline (Pursuing LPs)
```
Stages:
1. Identified (system recommended)
2. Shortlisted (GP interested)
3. Researching
4. Intro Requested / Cold Outreach Sent
5. Awaiting Response
6. Response Received
7. Meeting Scheduled
8. Meeting Completed
9. DD In Progress
10. Committed / Passed
```

#### LP: Interest Pipeline (Evaluating GPs)
```
Stages:
1. Recommended (system recommended)
2. Watchlisted (LP interested)
3. Reviewing
4. Meeting Requested (by LP)  â†â”€â”€ LP can initiate!
5. OR: Inbound Request (from GP)
6. Meeting Scheduled
7. Meeting Completed
8. DD In Progress
9. Committed / Passed
```

#### LP Interest Pipeline UI
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ LP Interest Pipeline - PE Allocation 2025                       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                  â”‚
â”‚ Pipeline View | List View | Calendar View                       â”‚
â”‚                                                                  â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”‚
â”‚ â”‚ Review  â”‚Requestedâ”‚ Inbound â”‚ Meeting â”‚ DD      â”‚Committedâ”‚  â”‚
â”‚ â”‚   (12)  â”‚   (3)   â”‚   (8)   â”‚   (5)   â”‚   (2)   â”‚   (1)   â”‚  â”‚
â”‚ â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤  â”‚
â”‚ â”‚         â”‚         â”‚         â”‚         â”‚         â”‚         â”‚  â”‚
â”‚ â”‚Acme III â”‚Peak II  â”‚Blue IV  â”‚Growth   â”‚Venture  â”‚Alpha    â”‚  â”‚
â”‚ â”‚Score:94 â”‚Score:87 â”‚Score:82 â”‚Score:89 â”‚Score:85 â”‚Score:91 â”‚  â”‚
â”‚ â”‚         â”‚         â”‚         â”‚         â”‚         â”‚         â”‚  â”‚
â”‚ â”‚Gamma II â”‚         â”‚Delta IIIâ”‚Summit   â”‚         â”‚         â”‚  â”‚
â”‚ â”‚Score:88 â”‚         â”‚Score:78 â”‚Score:86 â”‚         â”‚         â”‚  â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â”‚
â”‚                                                                  â”‚
â”‚ Key:                                                             â”‚
â”‚ â€¢ Review = LP proactively researching                           â”‚
â”‚ â€¢ Requested = LP requested meeting with GP                      â”‚
â”‚ â€¢ Inbound = GP requested meeting with LP                        â”‚
â”‚                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### 18.6 Content Generation Symmetry

#### GP: Pitch Generation
- Executive summary tailored to LP
- Personalized outreach email
- Talking points for LP's interests
- Objection handling prep

#### LP: Meeting Request Generation
- Interest summary explaining why this fund
- Personalized meeting request email
- Questions to ask the GP
- Evaluation criteria prep

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Generate Meeting Request - Acme Capital Fund III                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                  â”‚
â”‚ Why This Fund Matches Your Mandate                               â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ âœ“ Strategy: Growth equity - matches your target allocation  â”‚ â”‚
â”‚ â”‚ âœ“ Geography: North America & Europe - within your mandate   â”‚ â”‚
â”‚ â”‚ âœ“ Fund Size: $500M - fits your check size ($15-30M)         â”‚ â”‚
â”‚ â”‚ âœ“ Track Record: Fund II returned 2.1x - above your hurdle   â”‚ â”‚
â”‚ â”‚ âš  Sector: Heavy tech focus - monitor concentration          â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                                  â”‚
â”‚ Generated Meeting Request Email                                  â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ To: [john@acmecapital.com]                                  â”‚ â”‚
â”‚ â”‚ Subject: CalPERS Interest in Acme Capital Fund III          â”‚ â”‚
â”‚ â”‚                                                             â”‚ â”‚
â”‚ â”‚ Dear John,                                                  â”‚ â”‚
â”‚ â”‚                                                             â”‚ â”‚
â”‚ â”‚ I'm reaching out from CalPERS' Private Equity team. We've  â”‚ â”‚
â”‚ â”‚ been following Acme Capital's progress and are impressed   â”‚ â”‚
â”‚ â”‚ with Fund II's performance in the growth equity space.     â”‚ â”‚
â”‚ â”‚                                                             â”‚ â”‚
â”‚ â”‚ As we build out our 2025 PE allocation, Fund III appears   â”‚ â”‚
â”‚ â”‚ to align well with our mandate. We'd welcome the           â”‚ â”‚
â”‚ â”‚ opportunity to learn more about your investment thesis     â”‚ â”‚
â”‚ â”‚ and current pipeline.                                      â”‚ â”‚
â”‚ â”‚                                                             â”‚ â”‚
â”‚ â”‚ Would you be available for a 30-minute introductory call   â”‚ â”‚
â”‚ â”‚ in the coming weeks?                                       â”‚ â”‚
â”‚ â”‚                                                             â”‚ â”‚
â”‚ â”‚ Best regards,                                               â”‚ â”‚
â”‚ â”‚ Sarah Chen                                                  â”‚ â”‚
â”‚ â”‚ Director, Private Equity                                    â”‚ â”‚
â”‚ â”‚ CalPERS                                                     â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                                  â”‚
â”‚ Questions to Prepare                                             â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ 1. What's your current deployment pace for Fund III?       â”‚ â”‚
â”‚ â”‚ 2. How does the tech concentration compare to Fund II?     â”‚ â”‚
â”‚ â”‚ 3. What's your approach to ESG in portfolio companies?     â”‚ â”‚
â”‚ â”‚ 4. Co-investment rights and fees?                          â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                                  â”‚
â”‚                   [Copy Email] [Send Request] [Save Draft]      â”‚
â”‚                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### 18.7 Notification Symmetry

#### GP Notifications
- New LP recommendations
- LP responded to outreach
- Meeting scheduled
- LP started DD
- LP committed

#### LP Notifications
- New fund recommendations
- GP requested meeting
- GP followed up
- Meeting scheduled
- DD materials received
- GP fund closing soon (urgency)

---

### 18.8 Agent Symmetry (36 Agents)

The 36-agent architecture works in both directions with adjusted prompts:

| Debate | GPâ†’LP Focus | LPâ†’GP Focus |
|--------|-------------|-------------|
| Constraint Interpretation | LP mandate flexibility | Fund thesis flexibility |
| Research Enrichment | LP data gaps | GP data gaps |
| Match Scoring | LP fit for fund | Fund fit for mandate |
| Pitch Generation | Pitch to LP | Meeting request to GP |
| Relationship Intelligence | Path to LP | Path to GP |
| Timing Analysis | When to approach LP | When to approach GP |
| Competitive Intelligence | Other GPs pursuing LP | Other LPs in fund |
| Objection Handling | LP concerns | GP concerns |
| Persona Analysis | LP decision-maker style | GP team style |
| Market Context | LP market conditions | GP fundraising conditions |
| Prioritization | Which LPs to pursue | Which funds to prioritize |

---

### 18.9 Data Model Symmetry

#### GP-Centric Tables (Existing)
```sql
client_funds          -- GP's funds
outreach_activities   -- GP â†’ LP tracking
fund_lp_matches       -- GP's view of LP matches
```

#### LP-Centric Tables (New/Enhanced)
```sql
client_mandates       -- LP's mandates
interest_activities   -- LP's tracking of funds
mandate_fund_matches  -- LP's view of fund matches
```

#### Enhanced Interest Activities Table

```sql
CREATE TABLE interest_activities (
    id UUID PRIMARY KEY DEFAULT gen_random_uuid(),

    -- LP mandate
    mandate_id UUID NOT NULL REFERENCES client_mandates(id),

    -- GP fund being evaluated
    fund_id UUID NOT NULL REFERENCES client_funds(id),
    gp_company_id UUID NOT NULL REFERENCES companies(id),

    -- Current status
    stage TEXT NOT NULL DEFAULT 'recommended',
    -- Stages: recommended, watchlisted, reviewing, meeting_requested,
    --         inbound_request, meeting_scheduled, meeting_completed,
    --         dd_in_progress, committed, passed

    -- Who initiated
    initiated_by TEXT,  -- 'lp' | 'gp' | 'system'

    -- Contact tracking
    primary_contact_id UUID REFERENCES people(id),
    last_contact_date TIMESTAMP,
    next_action_date TIMESTAMP,
    next_action_description TEXT,

    -- Match data
    match_score NUMERIC,
    match_reasons JSONB,

    -- Outcome
    commitment_amount_mm NUMERIC,
    passed_reason TEXT,

    created_at TIMESTAMP DEFAULT NOW(),
    updated_at TIMESTAMP DEFAULT NOW()
);
```

---

### 18.10 UI Files to Create/Update

| GP Screen | LP Equivalent | File |
|-----------|---------------|------|
| `gp-dashboard.html` | `lp-dashboard.html` | EXISTS |
| `shortlist.html` | `lp-watchlist.html` | NEW |
| `fund-profile.html` | `lp-mandate-profile.html` | NEW |
| `pitch-generator.html` | `lp-meeting-request.html` | NEW |
| `gp-settings.html` | `lp-settings.html` | EXISTS |
| N/A | `lp-inbound-requests.html` | NEW |

---

### 18.11 Implementation Phasing

**Phase 1 (M1-M4): GPâ†’LP**
- GP creates fund, gets LP matches
- GP shortlists and reaches out
- All current milestones

**Phase 2 (M5): LPâ†’GP**
- LP creates mandate, gets fund matches
- LP watchlists and reviews
- LP receives inbound GP requests
- LP initiates meeting requests

**Phase 3 (M6): Full Bidirectional**
- Both sides fully active
- Cross-platform notifications
- Mutual interest detection
- "You both want to meet" alerts

---

### 18.12 Mutual Interest Feature

When both sides express interest:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¯ Mutual Interest Detected!                                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                  â”‚
â”‚ CalPERS added Acme Capital Fund III to their watchlist          â”‚
â”‚ while you have CalPERS on your shortlist!                       â”‚
â”‚                                                                  â”‚
â”‚ Both parties interested â†’ Higher success probability            â”‚
â”‚                                                                  â”‚
â”‚ [Schedule Meeting Now]  [View CalPERS Profile]                  â”‚
â”‚                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

*Section 18 complete. Full bidirectional feature symmetry documented.*

---

